CGTLive’s Weekly Rewind – June 30, 2023


Review top news and interview highlights from the week ending June 30, 2023.

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA Approves BioMarin’s Hemophilia A Gene Therapy Roctavian

The FDA’s decision to approve this first gene therapy in hemophilia A was based on data from the phase 3 GENEr8-1 clinical trial.

2. Frank Borriello, MD, PhD, on Next Steps for SUPLEXA-101 for Solid Tumors

The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed progress of the phase 1 trial and possible future evaluations of the therapy.

3. FDA Approves Lantidra Cell Therapy for Type 1 Diabetes

With an original PDUFA date in August 2021, the decision is a long time coming.

4. James Gulley, MD, PhD, FACP, on Assessing a Novel TCR Bifunctional Antibody in CPI-Resistant Solid Tumors

The director of the Medical Oncology Service at the National Cancer Institute discussed the START-001 trial.

5. Gene Therapy Modifies Disease Progression in Patients With Giant Axonal Neuropathy

Taysha also provided updates on its gene therapy program for Rett syndrome.

Related Videos
Evan Weber, PhD, an assistant professor of pediatrics at Children's Hospital of Philadelphia
Shankar Ramaswamy, MD, the cofounder, chairman, and CEO of Kriya Therapeutics
Kevin Campbell, PhD, a Howard Hughes Investigator at the University of Iowa
Debora Mazzetti, MS, on Multitargeting MicroRNA in Glioblastoma
Francesca Del Bufalo, MD, PhD, a medical doctor and scientist at Bambino Gesù Chidren’s Hospital
Travis Drow, BS, a research scientist at Seattle Children's Research Institute
Carlos Ramos, MD, on Alternatives to T-Cell Therapy
Omer A. Abdul Hamid, MD, on Sharing Expertise With Gene Therapy Logistics
© 2024 MJH Life Sciences

All rights reserved.